NCT01715935View on ClinicalTrials.gov

Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

June 30, 2015

Study Completion Date

April 30, 2016

Conditions
Clear-cell Renal CarcinomaClear-cell Metastatic Renal Cell Carcinoma
Interventions
DRUG

Everolimus

everolimus, 10 mg PO daily. Before nephrectomy: 6 continuous weeks of treatment and one week of rest After nephrectomy: 4 weeks courses (for metastatic patients only)

Trial Locations (10)

7505

Hôpital Européen Georges Pompidou - Service d'oncologie médicale, Paris

25000

CHRU Besançon, Besançon

42270

Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez

54511

Centre Alexis Vautrin, Vandœuvre-lès-Nancy

75005

Fôpital d'Instruction des Amées du Val de Grâce, Paris

75014

Hôpital Cochin, Paris

94000

Hôpital Henri Mondor, Créteil

85925 cedex 9

Centre Hospitalier Départemental Vendée, La Roche-sur-Yon

34285 cedex 5

Hôpital Saint Eloi - CHU Montpellier, Montpellier

94805 cedex

Institut Gustave Roussy, Villejuif

All Listed Sponsors
lead

Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie

OTHER

NCT01715935 - Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus | Biotech Hunter | Biotech Hunter